Immediate-release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder

Area of Science:

• Pediatric Neurology
• Child Psychiatry
• Neurodevelopmental Disorders

Background:

• Attention-deficit/hyperactivity disorder (ADHD) often co-occurs with tic disorders in children.
• Managing ADHD in children with comorbid tic disorders presents unique treatment challenges.
• Immediate-release methylphenidate (MPH-IR) is a common ADHD pharmacotherapy, but its use in tic disorder populations requires careful evaluation.

Purpose of the Study:

• To assess the safety and efficacy of MPH-IR for treating ADHD in children aged 6-12 years with concurrent Tourette's syndrome or chronic motor tic disorder.
• To determine if MPH-IR influences the severity of tic disorder or obsessive-compulsive disorder symptoms.
• To evaluate behavioral improvements in ADHD, oppositional defiant disorder, and peer aggression.

Main Methods:

• A double-blind, placebo-controlled study involving two cohorts of prepubertal children (N=71).
• Participants received placebo and three doses of MPH-IR (0.1, 0.3, 0.5 mg/kg) twice daily for 2-week periods.
• Treatment effects were evaluated using a comprehensive battery of rating scales (parent, teacher, child, physician) and laboratory tasks.

Main Results:

• MPH-IR demonstrated significant efficacy in suppressing ADHD, oppositional defiant disorder, and peer aggression behaviors.
• No evidence suggested MPH-IR altered the overall severity of tic disorder or obsessive-compulsive disorder.
• Teacher-reported data indicated a decrease in tic frequency and severity with MPH-IR treatment.

Conclusions:

• MPH-IR appears to be a safe and effective short-term treatment for ADHD in most children with chronic tic disorder.
• Close monitoring for potential tic exacerbation in susceptible individuals is crucial.
• The findings support the judicious use of MPH-IR in this pediatric population under careful supervision.